Cite

HARVARD Citation

    Decaens, T. et al. (n.d.). 152OEfficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. Annals of oncology. p. . [Online]. 
  
Back to record